Table of Contents
Overview
New York, NY – Oct 22, 2025 – Global Rat and Mouse Model Market size is expected to be worth around US$ 3.0 Billion by 2033 from US$ 1.6 Billion in 2024, growing at a CAGR of 7.1% during the forecast period 2025 to 2033.
The Rat and Mouse Model Market is experiencing robust growth, supported by increasing demand for reliable preclinical research models in pharmaceuticals, biotechnology, and academic research institutions. These models remain indispensable in studying disease mechanisms, evaluating therapeutic efficacy, and advancing drug discovery and development.
The global market’s expansion is primarily attributed to the growing prevalence of chronic and infectious diseases, rising R&D investments, and technological advancements in genetic engineering. The development of genetically modified and humanized rodent models has revolutionized biomedical research, enabling precise disease modeling and more accurate prediction of human responses to new therapies.
Additionally, the integration of CRISPR and other genome-editing technologies has accelerated the creation of transgenic models, significantly improving experimental efficiency. Increased funding from government and private organizations for biomedical and cancer research is further stimulating market growth.
Pharmaceutical and biotechnology companies are adopting rat and mouse models extensively for toxicity testing, pharmacokinetics, and safety assessment in early-stage drug development. Academic and research institutions also continue to utilize these models for neuroscience, immunology, and metabolic studies.
North America dominates the global market due to advanced research infrastructure and strong government support for life science research. However, the Asia Pacific region is anticipated to register the fastest growth, driven by rising R&D activities and expanding pharmaceutical production capabilities.
Key Takeaways
- Global Rat and Mouse Model Market size is expected to be worth around US$ 3.0 Billion by 2033 from US$ 1.6 Billion in 2024, growing at a CAGR of 7.1% during the forecast period 2025 to 2033.
- Based on product type, the market is segmented into model and service categories. The model segment dominated in 2023, accounting for a 68.2% share, primarily due to the widespread use of genetically modified and inbred models in preclinical research and drug discovery.
- By application, the market is classified into cancer, genetic diseases, cardiovascular diseases, infectious diseases, transplantation, and others. Among these, the cancer segment held a significant share of 55.6%, supported by the increasing prevalence of cancer and rising research investments in oncology drug development.
- Considering end use, the market is segmented into pharmaceutical and biotechnology companies, contract research and manufacturing organizations (CROs/CMOs), and academic and research facilities. The pharmaceutical and biotechnology companies segment led the market with a 61.5% revenue share, driven by extensive use of rodent models in preclinical testing and safety evaluation.
- Regionally, North America dominated the global market, capturing 38.7% of the total share in 2023, owing to advanced research infrastructure, strong funding support, and the presence of leading biotechnology and pharmaceutical firms.
Segmentation Analysis
Product Type Analysis
In 2023, the model segment accounted for 68.2% of the market share, primarily driven by the rising demand for advanced and precise research tools. Genetically modified rat and mouse models have gained significant adoption for replicating human disease pathways in drug discovery and toxicology studies.
Continuous advancements in model development especially for targeted disease research and the growing focus on personalized medicine are expected to enhance segment growth further. Moreover, increasing biomedical research funding is anticipated to strengthen market expansion in the coming years.
Application Analysis
The cancer segment dominated the market in 2023, representing 55.6% of the total share. Rat and mouse models play a pivotal role in studying tumor development, disease progression, and therapeutic responses. The global rise in cancer prevalence has amplified the demand for reliable preclinical testing platforms.
These models remain essential for evaluating immuno-oncology treatments and personalized therapies. Additionally, stringent regulatory guidelines promoting the use of validated preclinical models are expected to accelerate the adoption of rat and mouse models in oncology research.
End-use Analysis
In 2023, pharmaceutical and biotechnology companies held a 61.5% share of the market, reflecting their increasing dependence on animal models for preclinical testing. These models are vital for assessing the safety and efficacy of new drug candidates before entering clinical stages.
The segment is projected to expand with growing R&D investments in gene therapies, biologics, and immunotherapies. Furthermore, as regulatory compliance standards tighten, the demand for genetically engineered and disease-specific models is likely to increase, supporting faster and more reliable drug development outcomes.
Regional Analysis
North America dominated the market with the highest revenue share of 38.7% owing to advancements in biomedical research and an increasing demand for more accurate and human-relevant preclinical testing models. As the biopharmaceutical industry continues to expand, these models play a crucial role in drug discovery, toxicology testing, and disease modeling.
The growing focus on personalized medicine and immunotherapies has further spurred the adoption of genetically engineered rat and mouse models, which provide more precise insights into human disease mechanisms. A key development in this regard was achieved by scientists at The University of Texas Health Science Center in San Antonio in July 2024, when they created a humanized mouse model with a human immune system and gut microbiota, which is expected to significantly advance immunotherapy development.
The increasing need for reliable models for studying chronic diseases, including cancer, neurological disorders, and metabolic diseases, has further contributed to the market’s growth. Additionally, rising investments in research and development and a favorable regulatory environment in North America have fueled the demand for advanced rodent models in preclinical studies, ensuring continued market expansion.
The Asia Pacific region is expected to experience the highest CAGR during the forecast period
Asia Pacific is expected to grow with the fastest CAGR owing to the increasing investments in biomedical research and the rapid expansion of the pharmaceutical and biotechnology sectors. As the region focuses on improving healthcare outcomes and reducing reliance on animal testing, demand for high-quality and more human-relevant animal models is likely to rise.
Countries like China, India, and Japan are projected to increase their research efforts in areas such as cancer, infectious diseases, and neurodegenerative conditions, fueling the need for advanced rodent models in preclinical studies. The growing adoption of genetically modified rat and mouse models for studying complex diseases and the rising focus on precision medicine are expected to further propel the market.
Additionally, government initiatives and funding to enhance research infrastructure in the region are anticipated to drive market growth. The demand for reliable disease models in drug discovery and development, coupled with the increasing number of clinical trials, will likely contribute to the sustained growth of the rat and mouse model market in Asia Pacific.
Frequently Asked Questions on Rat and Mouse Model
- What are rat and mouse models used for in research?
Rat and mouse models are widely used in biomedical research to study human diseases, genetics, and drug responses. Their genetic similarity to humans enables scientists to understand disease mechanisms and evaluate new treatments before clinical trials. - Why are rodents preferred in laboratory research?
Rodents are preferred due to their small size, short life cycle, and ease of genetic manipulation. They reproduce quickly, allowing researchers to observe multiple generations and evaluate genetic and physiological changes efficiently and cost-effectively. - What are transgenic rat and mouse models?
Transgenic models are genetically modified rodents with inserted or deleted genes. These models help researchers investigate gene function, mimic human disease conditions, and test potential therapeutic interventions with a high degree of biological relevance. - How are rat and mouse models maintained in laboratories?
Rodents are housed in controlled environments with regulated temperature, humidity, and lighting. They receive specific diets and veterinary care to ensure health and consistency, maintaining reliable results across scientific and pharmaceutical experiments. - What are ethical considerations in using animal models?
Ethical guidelines require minimizing animal suffering through humane handling and justified use. Institutions must follow regulations such as the “3Rs”—Replacement, Reduction, and Refinement—to ensure responsible and ethical animal experimentation. - Which regions dominate the rat and mouse model market?
North America dominates due to advanced research infrastructure, government funding, and strong pharmaceutical R&D. Europe and Asia-Pacific are witnessing rapid growth owing to increasing investments in biotechnology and expanding laboratory animal facilities. - Who are the key players in the rat and mouse model market?
Prominent players include Charles River Laboratories, Taconic Biosciences, Envigo, Janvier Labs, and The Jackson Laboratory. These companies specialize in breeding, genetic engineering, and providing specialized disease and transgenic models for global research needs.
Conclusion
The Rat and Mouse Model Market is poised for steady expansion, driven by the rising need for precise preclinical models in pharmaceutical, biotechnology, and academic research. Advancements in genetic engineering, including CRISPR technology, have enhanced disease modeling accuracy and research efficiency. Increasing R&D investments, supportive government funding, and growing prevalence of chronic diseases further strengthen market growth.
North America currently leads due to robust infrastructure, while Asia Pacific is expected to record the fastest growth. The market’s future remains promising, supported by continued innovation, ethical research practices, and expanding applications in personalized and precision medicine.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
